主要目的：比较空腹及餐后给药条件下，上海安必生制药技术有限公司提供的枸橼酸托瑞米芬片（规格：60 mg（以托瑞米芬计））与芬兰 Orion Corporation 公司持证生产的枸橼酸托瑞米芬片（规格：60 mg（以托瑞米芬计），商品名：法乐通®（Fareston®））在健康人群中吸收程度和速度的差异。次要目的：评价空腹及餐后条件下，上海安必生制药技术有限公司提供的枸橼酸托瑞米芬片（规格：60 mg（以托瑞米芬计））与芬兰 Orion Corporation 公司持证生产的枸橼酸托瑞米芬片（规格：60 mg（以托瑞米芬计），商品名：法乐通®（Fareston®））的安全性。

[Translation]

Primary objective: To compare the differences in absorption degree and speed of toremifene citrate tablets (specification: 60 mg (in toremifene)) provided by Shanghai Anbisheng Pharmaceutical Technology Co., Ltd. and toremifene citrate tablets (specification: 60 mg (in toremifene), trade name: Fareston®) produced by Orion Corporation of Finland under fasting and postprandial administration conditions in healthy people. Secondary objective: To evaluate the safety of toremifene citrate tablets (specification: 60 mg (in toremifene)) provided by Shanghai Anbisheng Pharmaceutical Technology Co., Ltd. and toremifene citrate tablets (specification: 60 mg (in toremifene), trade name: Fareston®) produced by Orion Corporation of Finland under fasting and postprandial administration conditions.

Start Date27 Jun 2024

Sponsor / Collaborator

Shanghai Anbison Laboratories Co., Ltd.

CTR20240551 / CompletedNot Applicable

枸橼酸托瑞米芬片在健康受试者中空腹和餐后给药条件下单中心、单剂量、随机、开放、交叉设计生物等效性试验

[Translation] A single-center, single-dose, randomized, open-label, crossover bioequivalence study of toremifene citrate tablets in healthy subjects under fasting and fed conditions

主要目的：为成都倍特药业股份有限公司生产的枸橼酸托瑞米芬片（规格：60mg）为受试制剂，原研（Orien Corporation）公司持有的枸橼酸托瑞米芬片（规格：60mg；商品名：法乐通® /Fareston®）为参比制剂，研究受试制剂和参比制剂在健康志愿者空腹和餐后条件下单剂量给药时的药代动力学相似性。次要目的：观察受试制剂和参比制剂在健康受试者中的安全性。

[Translation]

Primary objective: Toremifene citrate tablets (specification: 60 mg) produced by Chengdu Beite Pharmaceutical Co., Ltd. were used as the test preparation, and Toremifene citrate tablets (specification: 60 mg; trade name: Fareston® /Fareston®) held by Orien Corporation were used as the reference preparation to study the pharmacokinetic similarity of the test preparation and the reference preparation when administered in a single dose in healthy volunteers under fasting and postprandial conditions. Secondary objective: To observe the safety of the test preparation and the reference preparation in healthy subjects.

Start Date25 Feb 2024

Sponsor / Collaborator

Brilliant Pharmaceutical Co. Ltd.

CTR20234215 / CompletedNot Applicable

枸橼酸托瑞米芬片在健康成年受试者中单次空腹状态及高脂餐后口服给药的随机、开放、两周期、两序列、交叉设计生物等效性试验方案

[Translation] A randomized, open-label, two-period, two-sequence, crossover bioequivalence study of toremifene citrate tablets in healthy adult subjects after single oral administration in the fasting state and after a high-fat meal

主要研究目的：研究重庆圣华曦药业股份有限公司生产的枸橼酸托瑞米芬片（规格：60mg）在中国健康受试者中空腹状态及高脂餐后以口服途径单次给药的药代动力学特征，并以 Orion Corporation 持有，Orion Corporation 生产的枸橼酸托瑞米芬片（商品名：法乐通®、FARESTON®；规格：60mg）为参比制剂，进行生物等效性评价。次要研究目的：初步考察枸橼酸托瑞米芬片受试制剂和参比制剂在健康受试者中的安全性。

[Translation]

Primary study objective: To study the pharmacokinetic characteristics of toremifene citrate tablets (specification: 60 mg) produced by Chongqing Shenghuaxi Pharmaceutical Co., Ltd. in healthy Chinese subjects in the fasting state and after a high-fat meal, and to evaluate the bioequivalence of toremifene citrate tablets (trade name: FARESTON®, FARESTON®; specification: 60 mg) owned by Orion Corporation and produced by Orion Corporation as the reference preparation. Secondary study objective: To preliminarily investigate the safety of the test preparation and reference preparation of toremifene citrate tablets in healthy subjects.

Start Date21 Dec 2023

Sponsor / Collaborator

Chongqing Shenghuaxi Pharmaceutical Co. Ltd.

100 Clinical Results associated with Toremifene Citrate

100 Translational Medicine associated with Toremifene Citrate

100 Patents (Medical) associated with Toremifene Citrate

724

Literatures (Medical) associated with Toremifene Citrate

01 Oct 2024·MedComm

Patient‐reported outcome and survival in premenopausal hormone receptor‐positive breast cancer patients at moderate to high risk: comparing toremifene with aromatase inhibitor in a real‐world study

Article

Author: Yang, Yaping ; Zhang, Wei ; Yang, Wenqian ; Chen, Lili ; Gong, Chang ; Liu, Qiang ; Lin, Qun ; Gan, Fengxia ; Luo, Ting

Abstract:

Toremifene, a selective estrogen receptor modulator, is commonly used in China for premenopausal breast cancer patients. This real‐world study aimed to compare patient‐reported outcome (PRO) and survival between toremifene and aromatase inhibitor (AI) plus ovarian function suppression (OFS) in patients with moderate‐/high‐risk premenopausal hormone receptor (HR)‐positive breast cancer. The primary endpoint was PROs, assessed using SF‐36 and EQ‐5D‐5L questionnaires between January and March 2023. A total of 392 patients were included, with 171 receiving toremifene and 221 receiving AI. The toremifene group showed significantly higher scores in the role physical (p = 0.034) and mental health (p = 0.009) dimensions of SF‐36 and lower anxiety/depression (AD) scores (p = 0.038) in EQ‐5D‐5L compared to AI group. The estimated 5‐ and 8‐year disease‐free survival (DFS) rates were similar in toremifene and AI groups: 96.5% versus 91.9%, and 87.4% versus 87.8% (p = 0.39), respectively. Adverse event rates were similar in two groups, except for a greater risk of endometrial thickening (p < 0.001) and a lower occurrence of morning stiffness (p < 0.001) in the toremifene compared to the AI group. Premenopausal HR‐positive breast cancer patients receiving toremifene plus OFS had better role physical and mental health outcomes and lower AD dimensions than those receiving AI plus OFS. Both treatments had comparable DFS and favorable tolerability profiles.

01 Aug 2024·TOXICOLOGICAL SCIENCES

Drug-induced impairment of mitochondrial fatty acid oxidation and steatosis: assessment of causal relationship with 45 pharmaceuticals

Article

Author: Martel, Cécile ; Borgne-Sanchez, Annie ; Porceddu, Mathieu ; Loyant, Roxane ; Fromenty, Bernard ; Buron, Nelly ; Allard, Julien A

Abstract:

Drug-induced liver injury (DILI) represents a major issue for pharmaceutical companies, being a potential cause of black-box warnings on marketed pharmaceuticals, or drug withdrawal from the market. Lipid accumulation in the liver also referred to as steatosis, may be secondary to impaired mitochondrial fatty acid oxidation (mtFAO). However, an overall causal relationship between drug-induced mtFAO inhibition and the occurrence of steatosis in patients has not yet been established with a high number of pharmaceuticals. Hence, 32 steatogenic and 13 nonsteatogenic drugs were tested for their ability to inhibit mtFAO in isolated mouse liver mitochondria. To this end, mitochondrial respiration was measured with palmitoyl-l-carnitine, palmitoyl-CoA + l-carnitine, or octanoyl- l-carnitine. This mtFAO tri-parametric assay was able to predict the occurrence of steatosis in patients with a sensitivity and positive predictive value above 88%. To get further information regarding the mechanism of drug-induced mtFAO impairment, mitochondrial respiration was also measured with malate/glutamate or succinate. Drugs such as diclofenac, methotrexate, and troglitazone could inhibit mtFAO secondary to an impairment of the mitochondrial respiratory chain, whereas dexamethasone, olanzapine, and zidovudine appeared to impair mtFAO directly. Mitochondrial swelling, transmembrane potential, and production of reactive oxygen species were also assessed for all compounds. Only the steatogenic drugs amiodarone, ketoconazole, lovastatin, and toremifene altered all these 3 mitochondrial parameters. In conclusion, our tri-parametric mtFAO assay could be useful in predicting the occurrence of steatosis in patients. The combination of this assay with other mitochondrial parameters could also help to better understand the mechanism of drug-induced mtFAO inhibition.

13 Mar 2024·Current computer-aided drug design

Molecular Docking and ADMET Analysis Strategy-Based Stability Indicating RP-HPLC-PDA Method Development and Validation of Toremifene

Article

Author: Ahmad, Makhmur ; Khan, Shamshir ; Hashmi, Sana ; Ali, Md Sajid ; Hudda, Sharwan ; Ullah, Zabih

Background::

The purpose of this research is to develop an analytical method and validate it according to ICH guidelines for the estimation of Toremifene by RP-HPLC-PDA with molecular docking and ADMET analysis. From molecular docking, it came to know the receptor affinity specifically to estrogen receptors (ERα and ERβ), which are responsible for cancer therapy. ADMET analyses secure its therapeutic potential as well safety of the drug.

background::

By performing Molecular docking analyses the precise interaction with target proteins have been confirmed, while ADMET assessments have unveiled its pharmacokinetic attributes and anticipated toxicity profile of drug.

Methods::

An isocratic method has developed by RP-HPLC-PDA (AGILENT 1100) with symmetry of 100 mm x 4.6 mm x 5 μm particle size C18 column and optimise mobile phase is methanol: 0.1% OPA (orthophosphoric acid) water ratio of 43:57% v/v. Under different conditions like acidic, alkaline, oxidative, and neutral environments, toremifene was tested for degradation.

objective::

Quantification of Toremifene by RP-HPLC-PDA analytical with Molecular docking approach

Results::

The developed method is validated in accordance with ICH guidelines. A calibration curve with an r2 value of 0.9987 has been prepared across the range of 10 to 50 μg/ml with five standard dilutions. The retention time of the drug is 5.575 minutes. The validation results are system suitability (%RSD-0.76), inter-day precision (%RSD 0.14-0.29), intraday precision (%RSD 0.08-0.34), accuracy (%RSD 0.16-0.96), and robustness (%RSD 0.16-0.35). In different intended conditions, four peaks are in 1 N HCl, two peaks in 1 N NaOH, three peaks in 10% H2O2 (1hr), and one peak in neutral

method::

Molecular docking based an isocratic RP-HPLC-PDA was performed on an HPLC apparatus (AGILENT 1100) with a symmetry of 100 mm x 4.6 mm and a 5 µm particle size C18 column and a methanol:0.1% OPA (orthophosphoric acid) water ratio of 43:57% v/v.

Conclusion::

Toremifene, a Selective Estrogen Receptor Modulator (SERM), Drug pharmacokinetic properties and receptor binding affinity results are helpful in designing the analytical method. Developing the RP-HPLC-PDA method is found to be novel, simple and precise. It could be used for testing toremifene in bulk and pharmaceutical tablet dosage forms in quality control, as well as stability tests.

News (Medical) associated with Toremifene Citrate

26 Aug 2024

·www.fiercepharma.com

With new focus, Kyowa Kirin pulls decades-old breast cancer drug Fareston from US market

Kyowa Kirin will no longer sell breast cancer drug Fareston, or toremifene, in the U.S. Breast cancer treatments have evolved dramatically over the years, so Kyowa Kirin has decided to stop selling a decades-old drug in the U.S.Starting Aug. 31, Kyowa Kirin will no longer distribute or fulfill orders for Fareston, or toremifene, presented in 60 mg tablets, in the U.S., the company said Friday. The last day for placing orders will be Aug. 29.“The decision aligns with the company’s Vision for 2030 and its focus on the discovery, development and delivery of novel therapies for patients,” the company said in a statement.Fareston is a hormone therapy that blocks estrogen receptors. Other drugs in the same selective estrogen receptor modulators (SERMs) class include tamoxifen, known under the brand names Nolvadex and Soltamox.These old therapies have been around for decades and have largely been replaced by newer meds, including selective estrogen receptor degraders (SERDs) such as AstraZeneca’s Faslodex. Fareston was approved by the FDA in 1997 to treat postmenopausal women with estrogen receptor-positive breast cancer.Kyowa Kirin has been selling Fareston in the U.S. through an agreement with Finish company Orion Corporation. The Japanese pharma has previously notified Orion and the FDA of its decision to discontinue Fareston. Kyowa Kirin stopped promoting Fareston more than five years ago, and demand has since declined thanks to generics and other available treatments, a company spokesperson told Fierce Pharma.“These conditions, along with the company’s forward-looking strategy focusing on novel medicines with life-changing value, informed our decision to stop distribution,” the spokesperson said. In 2023, Kyowa Kirin recorded no revenue from Fareston after reporting 0.1 billion Japanese yen (around $700,000) for two consecutive years prior. The number was again zero in the first half of 2024. Kyowa is shifting its focus on to novel antibody technologies and cell and gene therapies. As a result, the company recently unveiled a plan to significantly reduce its small molecule drug discovery research activities.The Japanese pharma also recently restructured its Asia-Pacific business, selling its entire operations in the Chinese mainland, including its five established brands in the country, to local firm WinHealth Pharma for about $104 million. Rights to several established medicines in South Korea, Malaysia, Thailand, Hong Kong, Macau and Taiwan were also offloaded.Editor's Note: The story has been updated with additional comments from a Kyowa Kirin spokesperson.

Drug ApprovalAcquisition

26 Oct 2021

·www.biospace.com

Adrenal Cortical Carcinoma Diagnosis and Treatment Market to Witness an Outstanding Growth by 2026

Adrenal cortex is the outer layer of the gland involved in production of lifesaving hormones such as mineralocorticoids and glucocorticoids (aldosterone and cortisol) required for metabolism and stress management. Adrenal glands are located on the top of the kidneys. Adrenal cortical carcinoma is the cancer of adrenal cortex. There are two types of tumor associated with adrenal cortex, such as functioning tumor and non-functioning tumor. Functioning tumor is responsible for increase in the production of adrenal hormones, whereas, non-functioning tumor does not affect hormonal production. Adrenal cortical carcinoma is generally a secondary type of cancer. It occurs when another form of cancer spreads into the adrenal glands. Request Brochure of Report - Increasing incidence of adrenal cortical carcinoma due to spread of other form of cancer, advancement in imaging technologies to identify adrenal cortical tumors specifically, growing healthcare expenditure, and rising number of cancer treatment centers across the world are some of the dominating factors expected to fuel the growth of the global adrenal cortical carcinoma diagnosis and treatment market during the forecast period. For instance, according to the Journal of Clinical Endocrinology & Metabolism, adrenal cortical carcinoma is a rare and highly aggressive malignancy. The incidence rate for adrenal cortical carcinoma is 0.7–2.0 cases per million people. The disease is more common in women. It is generally diagnosed in the age group of 40 and 50 years. However, high incidence of adrenal cortical carcinoma is recorded among children in Brazil due to the high prevalence of a specific TP53 germline mutation in them. Request for Custom Research - The global adrenal cortical carcinoma diagnosis and treatment market can be segmented based on type of test, type of therapy, end-user, and region. In terms of type of test used for the diagnosis of adrenal cortical carcinoma, the market can be divided into magnetic resonance imaging (MRI), computed tomography (CT) scan, positron emission tomography (PET) scan, and biopsy. In terms of type of therapy, the adrenal cortical carcinoma diagnosis and treatment market can be categorized into surgery, chemotherapy, other drug therapy, radiation therapy, and biologic therapy. The surgery therapy segment can be further categorized into laparoscopic surgeries and open surgeries. The chemotherapy segment can be classified based on the type of drug used for the treatment into mitotane and the combination therapy of cisplatin, doxorubicin (adriamycin), and etoposide (VP-16) plus mitotane. The other drug therapy segment involves treatment of hormonal effects caused by the tumor. Drugs included in this type of therapy are spironolactone, mifepristone, tamoxifen, toremifene, etc. The radiation therapy segment can be bifurcated into external beam radiation therapy and brachytherapy. In terms of end-user, the adrenal cortical carcinoma diagnosis and treatment market can be segmented into hospitals, specialty cancer clinics, diagnostic centers, and others. Pre Book Adrenal Cortical Carcinoma Diagnosis and Treatment Market Report at - Based on geography, the global adrenal cortical carcinoma diagnosis and treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the adrenal cortical carcinoma diagnosis and treatment market owing to high per capita disposable income and increasing incidence of the adrenal cortical carcinoma in the region. For instance, according to the American Cancer Society, adrenal tumors (most of which are benign adenomas) are found in 1 in every 10 people who undergo tests such as CT scan or MRI of the adrenal gland. Europe is expected to be the second leading market for semen analysis due to high awareness about early diagnosis and treatment of the disease, favorable reimbursement facilities, and increasing healthcare expenditure in the region. Asia Pacific can be considered as an emerging market for the diagnosis and treatment of adrenal cortical carcinoma. Key players operating in the global adrenal cortical carcinoma diagnosis and treatment market include HRA Pharma, ER Squibb & Sons LLC, Bristol-Myers Squibb Company, GE healthcare, WG Critical Care, LLC, David Bull Laboratories (Pty) Ltd., Mylan Pharmaceuticals, Fresenius Kabi, Pfizer, SINOVISION Technologies(Beijing) Co., Ltd., Hitachi Medical Systems, NeuroLogica Corp., and Digirad Corporation. More Trending Reports by Transparency Market Research: Smart Hospitals Market: The high prevalence of active COVID-19 (coronavirus) cases in the U.S., India, Brazil, and Russia has triggered innovations in humanoid robots. Stakeholders in the smart hospitals market are taking cues from Beijing-based robotics company CloudMinds, which is providing humanoid robots in hospitals to free up human medical staff and limit the possibility of virus spread. Nucleic Acid Extraction Instruments & Reagents Market: Food security and global health face a constant threat from various existing and new plant and human diseases that are primarily caused by fungi, viruses, and different types of pathogens. Over the past few decades, the outbreak of various diseases including swine flu, Ebola, SARS, MERS, and the most recent COVID-19 has led to considerable loss of human lives and hindered the growth of the economy in several regions. About Us Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals. Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories. TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision. Contact Mr. Rohit Bhisey Transparency Market Research State Tower, 90 State Street, Suite 700, Albany NY - 12207 United States USA - Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website:

Radiation Therapy

03 Aug 2006

·www.biospace.com

GTx, Inc. Announces Webcast Of Corporate Presentation At The Bank of America 2006 Specialty Pharmaceuticals Conference

MEMPHIS, Tenn., Aug. 3 /PRNewswire-FirstCall/ -- GTx, Inc. , the Men's Health Biotech Company, announced today that company management will present at the Bank of America Specialty Pharmaceuticals Conference at 1:30 p.m. Eastern time on August 10 at the Southampton Inn in Southampton, NY. The presentation will be simultaneously webcast. The link for the live webcast is . The presentation will also be accessible from the GTx website at . An archived replay of the presentation will be available until August 25, 2006. About GTx GTx, headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutics for cancer and serious conditions related to men's health. GTx's lead drug discovery and development programs are focused on small molecules that selectively modulate the effects of estrogens and androgens, two essential classes of hormones. GTx is developing ACAPODENE(R) (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first, a pivotal Phase III clinical trial for the treatment of serious side effects of androgen deprivation therapy for advanced prostate cancer, and second, a pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia, or PIN. GTx is developing ostarine, a selective androgen receptor modulator, or SARM, for muscle wasting and bone loss indications. Ostarine is currently being evaluated in a Phase II clinical trial in 120 elderly men and postmenopausal women. GTx expects to have data from the Phase II ostarine trial in the fourth quarter of 2006. GTx has licensed to Ortho Biotech Products, L.P., a subsidiary of Johnson & Johnson, another of its SARMs, andarine, under a joint collaboration and license agreement. Forward-Looking Information is Subject to Risk and Uncertainty This press release contains forward-looking statements based upon GTx's current expectations. Forward-looking statements involve risks and uncertainties. GTx's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risks that (i) GTx will not be able to commercialize its product candidates if clinical trials do not demonstrate safety and efficacy in humans; (ii) GTx may not able to obtain required regulatory approvals to commercialize its product candidates; (iii) GTx's clinical trials may not be completed on schedule, or at all, or may otherwise be suspended or terminated; and (iv) GTx could utilize its available cash resources sooner than it currently expects and may be unable to raise capital when needed, which would force GTx to delay, reduce or eliminate its product development programs or commercialization efforts. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. GTx's quarterly report on form 10-Q filed with the U.S. Securities and Exchange Commission on May 5, 2006, contains a more comprehensive description of these and other risks to which GTx is subject. GTx expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. GTx, Inc. CONTACT: McDavid Stilwell of GTx, Inc., +1-901-237-9640 Web site:

Small molecular drug

100 Deals associated with Toremifene Citrate

External Link

KEGG	Wiki	ATC	Drug Bank
D00967	Toremifene Citrate	L02BA02	DB00539

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Estrogen receptor-negative breast cancer	EU	Orion Oyj	14 Feb 1996
Estrogen receptor-negative breast cancer	IS	Orion Oyj	14 Feb 1996
Estrogen receptor-negative breast cancer	LI	Orion Oyj	14 Feb 1996
Estrogen receptor-negative breast cancer	NO	Orion Oyj	14 Feb 1996
Metastatic breast cancer	EU	Orion Oyj	14 Feb 1996
Metastatic breast cancer	IS	Orion Oyj	14 Feb 1996
Metastatic breast cancer	LI	Orion Oyj	14 Feb 1996
Metastatic breast cancer	NO	Orion Oyj	14 Feb 1996
Breast Cancer	JP	Orion Co., Ltd.	31 Mar 1995

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Precancerous Conditions	Phase 3	US	GTx, Inc.	01 Jan 2005
Precancerous Conditions	Phase 3	AR	GTx, Inc.	01 Jan 2005
Precancerous Conditions	Phase 3	CA	GTx, Inc.	01 Jan 2005
Prostatic Intraepithelial Neoplasia	Phase 3	US	GTx, Inc.	01 Jan 2005
Prostatic Intraepithelial Neoplasia	Phase 3	AR	GTx, Inc.	01 Jan 2005
Prostatic Intraepithelial Neoplasia	Phase 3	CA	GTx, Inc.	01 Jan 2005
Fractures, Bone	Phase 3	US	GTx, Inc.	01 Oct 2003
Fractures, Bone	Phase 3	MX	GTx, Inc.	01 Oct 2003
Osteoporosis	Phase 3	US	GTx, Inc.	01 Oct 2003
Osteoporosis	Phase 3	MX	GTx, Inc.	01 Oct 2003

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00106691 (CTgov)	Phase 3	Prostatic Cancer \| Prostatic Intraepithelial Neoplasia \| Precancerous Conditions	1,589	Placebo	upiiewsebw(ugywhzcsot) = tnxulkvjrt ppzhhptgya (vpobopwemm, eqwzdjelnx - fejcmvzgwn) View more	-	12 Jun 2023
NCT02344940 (Pubmed \| BMC Cancer)	Phase 4	Premenopausal breast cancer Adjuvant	92	Toremifene	iuheubormb(mlkmimylbc) = bzbnotmmmr ttmwpzuhmz (xwzbsavswi ) View more	-	16 Jul 2020
				Tamoxifen	iuheubormb(mlkmimylbc) = uvkfjnubhh ttmwpzuhmz (xwzbsavswi ) View more
NCT00106691 (Pubmed \| J Urol)	Phase 3	-	1,589	Toremifene citrate 20 mg	trzwtsexle(mreciwqyhq) = hrczxpbuch ftvnfsfzkg (gbgepktjzz ) View more	-	10 Feb 2013
				Placebo	trzwtsexle(mreciwqyhq) = yfgbqyrmtm ftvnfsfzkg (gbgepktjzz ) View more
NCT00129142 (Pubmed \| J Urol)	Phase 3	Prostatic Cancer	646	Toremifene	uusegjkjvl(yjalmnotkv) = zfrskrbooo gdaijlvuox (yhqzxduhoc, -1.5 to 75.0) View more	Positive	01 Jan 2013
				Placebo	uusegjkjvl(yjalmnotkv) = hzevqthmks gdaijlvuox (yhqzxduhoc ) View more
ASCO2011	Not Applicable	Aggressive Fibromatosis	27	Toremifene	xqraxyvzmd(vzyueeinwg) = wazzuaumyi zdovzqrfii (wqudfwiscr ) View more	-	20 May 2011
ASCO2010	Phase 3	Fractures, Bone	-	Toremifene 80 mg	gqmemzcuuq(vdajbtdanu): relative risk reduction = 79.5 (95% CI, 29.8 - 94.0)	Positive	20 May 2010
				Placebo
863 (AUA2010)	Not Applicable	-	1,284	Toremifene 80mg	smexdmwgsj(ctfjwvnbng): OR = 0.59 (95% CI, 0.36 - 1.0), P-Value = <0.05	-	01 Apr 2010
				Placebo
ASCO2009	Phase 3	-	1,382	Toremifene citrate	ycmiygltaq(ihkajrjwuj) = jarlvinlkf pmsnxuqnpz (zfqtolrcyf ) View more	-	20 May 2009
ASCO2005	Not Applicable	Breast Cancer	13	High-dose Toremifene	dgbhjkaoyi(wcsudqhxwg) = tympffsiqw gjlbwtmveo (usadbsewff ) View more	Positive	01 Jun 2005
ASCO2004	Phase 2	Breast Cancer Neoadjuvant	-	Toremifene (TOR)	xfttadcpai(ohhbdqpqmy) = urhisbulcx zcnqucjylx (khzjirgqim, 28 - 58)	-	15 Jul 2004

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis